Transdermal selegiline: a novel MAOI formulation for depression.
Howland
Robert H
RH
University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pennsylvania 15213, USA. HowlandRH@upmc.edu
D000279:Administration, Cutaneous; D003866:Depressive Disorder / Q000188:drug therapy*; D004032:Diet; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D012642:Selegiline / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology
D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline